AARD News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

AA

Mkt Cap

$84.5M

Volume

93.95K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

AARD DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARDRosen Law Firm is notifying investors in Aardvark Therapeutics, Inc. of an October 13, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Aardvark made materially false and misleading statements regarding the safety and prospects of its drug ARD-101, and failed to disclose material adverse facts about the company's business and operations.GlobeNewswire Inc. · Oct 11, 2026

AARD 截止日期通知：知名律師事務所 ROSEN 提醒 Aardvark Therapeutics, Inc. 投資人，應於證券集體訴訟重要期限 10 月 13 日之前委任法律律師 – AARDRosen Law Firm reminds investors in Aardvark Therapeutics who purchased securities during the IPO on February 13, 2025 through May 14, 2026 of an October 13, 2026 deadline to nominate a lead plaintiff. The lawsuit alleges that defendants made material false and misleading statements regarding the safety and commercial prospects of ARD-101, causing investor losses when the truth was revealed.GlobeNewswire Inc. · Oct 11, 2026

URGENT AARDVARK DEADLINE: Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 13thA class action lawsuit has been filed against Aardvark Therapeutics in the U.S. District Court for the Southern District of California. The lawsuit alleges that defendants made materially false and misleading statements in the company's IPO registration statement and throughout the class period (February 13, 2025 to May 14, 2026), specifically regarding the safety and commercial prospects of their drug ARD-101. Investors who purchased shares during this period can apply to be lead plaintiff by October 13, 2026.GlobeNewswire Inc. · Oct 10, 2026

AARD 4-DAY DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 13, 2026 Lead Plaintiff Deadline - HBSSHagens Berman announces a securities class action lawsuit against Aardvark Therapeutics for allegedly making materially false statements about ARD-101's safety. The company failed to disclose cardiac observations during trials, leading to a voluntary pause of the Phase 3 HERO trial in February 2026 (56% stock decline) and an FDA clinical hold in May 2026 (32.1% additional decline). Investors with substantial losses have until October 13, 2026, to become lead plaintiffs.GlobeNewswire Inc. · Oct 9, 2026

AARD DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARDRosen Law Firm announces a securities class action lawsuit against Aardvark Therapeutics, Inc. for allegedly making materially false and misleading statements regarding the safety and prospects of its drug ARD-101. Investors who purchased securities during the IPO on February 13, 2025 or between February 13, 2025 and May 14, 2026 may be eligible to join the class action. The deadline to serve as lead plaintiff is October 13, 2026.GlobeNewswire Inc. · Oct 9, 2026

Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your BehalfGrabar Law Office is investigating securities fraud and fiduciary duty breach claims against four companies: Aardvark Therapeutics for allegedly misrepresenting the safety profile of its drug candidate ARD-101 before a clinical hold was placed; Coastal Financial Corporation for failing to disclose deterioration in its CCBX partner loan portfolio and credit losses; Erasca, Inc. for making misleading statements about its ERAS-0015 therapy and improper comparisons to competitors; and New Era Energy & Digital for overstating progress on its data center project and allegedly engaging in fraudulent oil-and-gas schemes.GlobeNewswire Inc. · Oct 8, 2026

Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of DirectorsAardvark Therapeutics appointed David Zhang, Ph.D., MBA, as an independent board director, bringing over 25 years of clinical development and regulatory expertise from companies including MyoKardia, Genentech/Roche, Alumis, and Abivax. Zhang will support Aardvark's regulatory strategy for ARD-101, its lead candidate for Prader-Willi Syndrome treatment, at a critical juncture following an FDA clinical hold.GlobeNewswire Inc. · Oct 8, 2026

Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmA class action lawsuit has been filed against Aardvark Therapeutics, Inc. alleging securities fraud. The complaint claims that offering documents contained untrue statements and that the company made materially false and misleading statements regarding the safety and prospects of its drug ARD-101. Investors who purchased shares during the IPO on February 13, 2025, or between that date and May 14, 2026, may be eligible to join the case.GlobeNewswire Inc. · Oct 6, 2026

AARDVARK THERAPEUTICS (NASDAQ: AARD) SECURITIES CLASS ACTION: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Investors to Secure Counsel Before Important October 13 DeadlineRosen Law Firm announces a securities class action lawsuit against Aardvark Therapeutics, with an October 13, 2026 deadline for investors to serve as lead plaintiff. The lawsuit alleges that defendants made materially false and misleading statements regarding the safety and prospects of their drug candidate ARD-101, causing investor damages when the true details emerged.GlobeNewswire Inc. · Oct 6, 2026

AARDVARK DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARDRosen Law Firm has announced multiple securities class action lawsuits against Aardvark Therapeutics, FuelCell Energy, and XTI Aerospace. The primary case involves Aardvark Therapeutics, where investors claim the company made materially false statements about the safety and prospects of its ARD-101 drug candidate in its IPO registration statement and throughout the class period. Investors have until October 13, 2026 to become lead plaintiffs in the Aardvark case.GlobeNewswire Inc. · Oct 2, 2026

AA

AARDAardvark Therapeutics, Inc. Common Stock

AARD

Pay with—

Available Balance0.00

Your PositionYou don't own any AARD yet.

Related Tickers

Earnings